Menu
OKLAHOMA CITY, OK, AUSTIN, TX, USA; MELBOURNE, VICTORIA, AUSTRALIA, April 6, 2022 — Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display™ (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 ImmunoScape, a preclinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology, today announced that it has signed a licensing deal with Pure MHC, LLC, a target discovery and development company, to pursue TCR-T therapeutics against Pure MHC identified antigens in lung cancer, colorectal cancer, and other cancer indications.
February 16, 2022
Austin, Texas, USA — Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.
March 31, 2021
Austin, Texas, USA — Pure MHC, LLC, a target discovery and development
company, today announced the launch of its Peptide HLA Immunotherapy Data Resource
(“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a
leader in regenerative medicine, LifeNet Health.
March 16, 2021
OKLAHOMA CITY, OK AND AUSTIN, TX – The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.
March 20, 2020
February 13, 2019
Emergent Technologies, Inc. announced today that its portfolio company,
Receptor Logic, has entered into an exclusive License Agreement with Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for autoimmune diseases, asthma and
allergic diseases, and cancer.
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC)
announced an agreement with Pure MHC, an Emergent Technologies portfolio
company, for development of a novel assay for quality control that will be an
important component of ImmunoCellular’s ICT-107 phase 3 registrational
clinical program in newly diagnosed glioblastoma, anticipated to begin in the
second half of 2015.
June 22, 2015
A recent cancer study performed by the Washington University School of
Medicine in St. Louis has garnered significant interest from the science and
medical community. This research, led by Dr. Beatriz Carreno, tested the
ability of a personalized cancer vaccine to assist the immune system’s
effectiveness in attacking a patient’s specific tumor.
April 1, 2015
PhosImmune Inc. and PureMHC LLC today announced they have entered into a
license and collaboration agreement to develop novel antibody-based
immunotherapies designed to target cancers.
October 21, 2014
Pure MHC, LLC
Administrative Office
7500 Rialto Blvd.
Building Two, Suite 260
Austin, TX 78735
Research Laboratory
655 Research Parkway
Suite 556
Oklahoma City, OK 73104
